Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Alcohol Liver Disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    96 result(s) found for: Alcohol Liver Disease. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2020-000829-55 Sponsor Protocol Number: PSILO4ALCO Start Date*: 2020-12-16
    Sponsor Name:Psychiatric Centre Copenhagen
    Full Title: Can a one-off administration of psilocybin reduce alcohol intake in patients with alcohol use disorder? A randomized, double-blinded, placebo-controlled clinical trial.
    Medical condition: Alcohol Use Disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10001594 Alcohol dependence syndrome LLT
    21.1 100000004873 10001590 Alcohol addiction LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-002334-11 Sponsor Protocol Number: 12014A Start Date*: 2009-03-13
    Sponsor Name:H. Lundbeck A/S
    Full Title: Nalmefene Efficacy Study I: Randomised, double-blind, placebo-controlled, parallel-group, efficacy study of 20 mg nalmefene, as needed use, in patients with alcohol dependence
    Medical condition: Alcohol dependence
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001594 Alcohol dependence syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) SE (Completed) FI (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-002315-92 Sponsor Protocol Number: 12013A Start Date*: 2008-11-12
    Sponsor Name:H. Lundbeck A/S
    Full Title: A 52-week, randomised, double-blind, placebo-controlled, parallel-group, safety, tolerability and efficacy study of nalmefene, as needed use, in patients with alcohol dependence
    Medical condition: Alcohol dependence
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001594 Alcohol dependence syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed) EE (Completed) GB (Completed) LV (Completed) HU (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2007-002563-27 Sponsor Protocol Number: 12023A Start Date*: 2008-11-24
    Sponsor Name:H. Lundbeck A/S
    Full Title: Nalmefene Efficacy Study II: Randomised, double-blind, placebo-controlled, parallel-group, efficacy study of 20 mg nalmefene, as needed use, in patients with alcohol dependence
    Medical condition: Alcohol dependence
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001594 Alcohol dependence syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) PT (Completed) ES (Completed) IT (Completed) BE (Completed) PL (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2019-004740-30 Sponsor Protocol Number: PHRCN2018 Start Date*: 2021-09-15
    Sponsor Name:Centre Hospitalier Le Vinatier
    Full Title: Cannabidiol for reducing drinking in alcohol use disorder and modifying the effects of alcohol on the brain and the liver: a phase 2 clinical trial.
    Medical condition: CARAMEL is an exploratory phase-2 study conducted in subjects with AUD (alcohol use disorder) and current heavy drinking level, aiming to confirm the different properties of CBD observed in animal ...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10001590 Alcohol addiction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000413-31 Sponsor Protocol Number: 15871A Start Date*: 2014-07-24
    Sponsor Name:H. Lundbeck A/S
    Full Title: Exploratory, interventional, open-label, fixed-dose study with Selincro® as-needed use, in alcohol dependent patients with liver impairment
    Medical condition: Alcohol dependence and liver impairment related to alcohol consumption
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004873 10001594 Alcohol dependence syndrome LLT
    17.1 100000004871 10021520 Impaired liver function LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-001154-98 Sponsor Protocol Number: 15660A Start Date*: 2013-10-14
    Sponsor Name:H Lundbeck A/S [...]
    1. H Lundbeck A/S
    2.
    Full Title: Interventional, randomized, double-blind, cross-over, placebo-controlled study to investigate the effects of nalmefene after single dose on the blood oxygen level dependent (BOLD) fMRI signal in th...
    Medical condition: Nalmefene (Selincro) is indicated for the reduction of alcohol consumption in adults with alcohol dependence who have a high drinking risk level, without physical withdrawal symptoms and who do not...
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004873 10001594 Alcohol dependence syndrome LLT
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-004688-30 Sponsor Protocol Number: 15892A Start Date*: 2014-05-19
    Sponsor Name:H. Lundbeck A/S
    Full Title: Interventional, open-label study of 18 mg Selincro® as needed use, in the treatment of patients with alcohol dependence in primary care
    Medical condition: Alcohol Dependency
    Disease: Version SOC Term Classification Code Term Level
    16.1 10037175 - Psychiatric disorders 10037175 Psychiatric disorders SOC
    16.1 10037175 - Psychiatric disorders 10001594 Alcohol dependence syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-006227-38 Sponsor Protocol Number: 11.017 Start Date*: 2012-05-01
    Sponsor Name:Ove B. Schaffalitzky de Muckadell
    Full Title: “Assessment of fibrotic liver disease in a medical admission ward and intervention with losartan as antifibrotic therapy in patients with alcoholic liverdisease”
    Medical condition: Fibrotic alcoholic liver disease is in early stages often completely asymptomatic. Fully developed cirrhosis affect a wide range of physiological conditions. Eksamples are portal hypertension and f...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10019805 - Hepatobiliary disorders 10001627 Alcoholic liver disease PT
    14.1 10019805 - Hepatobiliary disorders 10001626 Alcoholic liver damage, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-004663-22 Sponsor Protocol Number: NRL972-05/2007 (ETOH) Start Date*: 2008-04-14
    Sponsor Name:Norgine Limited
    Full Title: A multi-centre, open short term follow-up Phase II study to evaluate the clearance of NRL972 in patients undergoing alcohol withdrawal commencing in a controlled clinical setting.
    Medical condition: Alcoholic liver disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001627 Alcoholic liver disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-005454-35 Sponsor Protocol Number: MG001 Start Date*: 2013-03-13
    Sponsor Name:Hanna Pitkänen
    Full Title: Can magnesium enhance blood coagulation amongst patients with alcohol induced liver cirrhosis?
    Medical condition: Liver transplant candidates with alcohol induced liver cirrhosis and hypomagnesemia (P-Mg under 0,71 or magnesium substitution at least 750 mg/day)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004871 10024667 Liver cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-006023-33 Sponsor Protocol Number: SIMFIB Start Date*: 2021-10-26
    Sponsor Name:Institut d’Investigacions Biomèdiques August Pi i Sunyer
    Full Title: Efficacy of simvastatin reducing liver fibrosis in patients with advanced fibrosis due to alcohol: a randomized, double-blind, placebo-controlled clinical trial.
    Medical condition: reduction of liver fibrosis in patients with advanced fibrosis due to alcohol
    Disease: Version SOC Term Classification Code Term Level
    20.1 10019805 - Hepatobiliary disorders 10001627 Alcoholic liver disease PT
    20.0 10019805 - Hepatobiliary disorders 10019668 Hepatic fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005730-11 Sponsor Protocol Number: K419 Start Date*: 2015-02-11
    Sponsor Name:KRANKENHAUS SALEM DER EVANG. STADTMISSION HEIDELBERG GGMBH
    Full Title: Effect of Clomethiazole (Distraneurin®) on CYP2E1 Activity, transaminases, Liver fat content, and liver stiffness during Alcohol Detoxification – a pilot Study
    Medical condition: Alcoholic liver disease in patients hospitalised for alcohol detoxification.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000963-15 Sponsor Protocol Number: MATCH0.1 Start Date*: 2016-01-19
    Sponsor Name:University of Edinburgh [...]
    1. University of Edinburgh
    2. NHS Lothian
    Full Title: MAcrophage Therapy for Liver Cirrhosis (MATCH)
    Medical condition: Liver Cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10024667 Liver cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-001969-33 Sponsor Protocol Number: TAK-242-2001 Start Date*: 2020-05-28
    Sponsor Name:Akaza Bioscience Limited
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Proof-of-Concept, Phase 2a Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-242 in Subj...
    Medical condition: Acute Alcoholic Hepatitis Causing Decompensation of Alcohol related Cirrhosis and Acute-on-Chronic Liver Failure
    Disease: Version SOC Term Classification Code Term Level
    20.1 10019805 - Hepatobiliary disorders 10001627 Alcoholic liver disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended) HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-001983-31 Sponsor Protocol Number: GT-031 Start Date*: 2021-05-04
    Sponsor Name:Galectin Therapeutics Inc.
    Full Title: A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Es...
    Medical condition: Esophageal Varices in NASH Cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10009214 Cirrhosis of liver without mention of alcohol LLT
    21.1 100000004856 10055489 Esophageal varices in cirrhosis of liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) GB (GB - no longer in EU/EEA) BE (Ongoing) PL (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004529-14 Sponsor Protocol Number: VTL-308 Start Date*: 2016-02-08
    Sponsor Name:Vital Therapies, Inc.
    Full Title: A RANDOMIZED, OPEN-LABEL, MULTICENTER, CONTROLLED, PIVOTAL STUDY TO ASSESS SAFETY AND EFFICACY OF ELAD® IN SUBJECTS WITH ALCOHOL-INDUCED LIVER DECOMPENSATION (AILD)
    Medical condition: Alcohol-Induced Liver Decompensation (AILD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) IE (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003146-36 Sponsor Protocol Number: RIAlta-1 Start Date*: 2023-11-15
    Sponsor Name:Vall d'Hebron Research Institute (VHIR)
    Full Title: Safety of Rifampicin at High Dose for the Treatment of Adult Subjects with Complex Drug Susceptible Pulmonary and Extrapulmonary Tuberculosis
    Medical condition: Pulmonary and extrapulmonary tuberculosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-001639-10 Sponsor Protocol Number: 787-201 Start Date*: 2023-06-09
    Sponsor Name:Intercept Pharmaceuticals, Inc.
    Full Title: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subje...
    Medical condition: Severe Alcohol-Associated Hepatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10001624 Alcoholic hepatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005563-27 Sponsor Protocol Number: VTI-208 Start Date*: 2013-07-26
    Sponsor Name:Vital Therapies, Inc.
    Full Title: A RANDOMIZED, OPEN-LABEL, MULTICENTER, CONTROLLED STUDY TO ASSESS SAFETY AND EFFICACY OF ELAD IN SUBJECTS WITH ALCOHOL-INDUCED LIVER DECOMPENSATION (AILD)
    Medical condition: Alcohol-induced liver decompensation (AILD)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10019805 - Hepatobiliary disorders 10019755 Hepatitis chronic active PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 19:06:18 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA